Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran

Iranian Journal of Pharmaceutical Research

Volumn 13, Issue SUPPL, 2014, Pages 225-234

  Khatibi, Mohsen ^a   Rasekh, Hamid Reza ^a   Shahverdi, Zohreh ^b   Jamshidi, Hamid Reza ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cost Effectiveness; HPV vaccine; Iran

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CHILD; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; IRAN; MIDDLE AGED; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; VACCINATION;

EID: 84894589384     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R and Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer (2007) 121: 621-632.
2. Parkin DM and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine (2006) 24: 11-25.
3. Tavajohi S, Rastegar H, Ostad SN, Rezayat SM and Ghahramani MH. Evaluation of Potency of Measles Vaccine used in Iran: Comparison of WHO and NIBSC Method in Cell Culture. Iran. J. Pharm. Res. (2005) 3: 155-160.
4. Koulova A, Tsui J and Irwin K. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries. Vaccine (2008) 26: 6529-6541.
5. Garnett GP, Kim JJ and French K. Chapter 21: modeling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine (2006) 24: 178-186.
6. Dasbach EJ, Elbasha EH and Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev. (2006) 28: 88-100.
7. Newall AT, Beutels P and Wood JG. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect. Dis. (2007) 7: 289-296.
8. Goldie S, Goldhaber-Fiebert JD and Garnett GP. Chapter 18: public health policy for cervical cancer prevention. The role of decision science, economic evaluation, and mathematical modeling. Vaccine (2006) 24: 155-163.
9. Institute of Medicine. Vaccines for the 21st century: a tool for decision making. Washington: National Academy of Sciences (2000).
10. Parkin DM and Bray F. the burden of HPV-related cancers. Vaccine. (2006) 24: 11-25.
11. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2007) 56: 1-24.
12. Clifford GM, Smith JS, Aguado T and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer. (2003) 89: 101-105.
13. Dunne EF and Markowitz LE. Genital human papillomavirus infection. Clin. Infect. Dis. (2006) 43: 624-629.
14. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, H Rashidi B, Akbari Sari A and Zendehdel K. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women-analyses of national data and systematic review of the literature. Gynecol. Oncol. (2013) 128: 277-281.
15. Greer CE, Wheeler CM, Ladner MB, BeutnerK, Coyne MY and Liang H. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J. Clin. Microbiol. (1995) 33: 2058-2063.
16. Insinga RP, Dasbach EJ and Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics (2005) 23: 1107-1122.
17. Fleurence RL, Dixon JM and Milanova TF. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am. J. Obstet. Gynecol. (2007) 196: 206-212.
18. Hu D and Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am. J. Obstet. Gynecol. (2008) 198: 1-7.
19. Sanders GD and Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis. (2003) 9: 37-48.
20. Kulasingam SL and Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 290: 781-789.
21. Goldie SJ, Kohli M and Grima D. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. (2004) 96: 604-615.
22. Brisson M, Van de Velde N and De Wals P. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine (2007) 25: 5399-5408.
23. Kulasingam S, Connelly L and Conway E. A costeffectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical cancer screening program. Sex Health (2007) 4: 165-175.
24. Giuliano AR. Human papillomavirus vaccination in males. Gynecol. Oncol. (2007) 107: 24-26.
25. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis. (2005) 191: 97-106.
26. Ministry of Health and medical education of Iran Iranian Annual National Cancer Registration Report (2008-2009).
27. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M and Bray F. Worldwide burden of cervical cancer in 2008. Ann. Oncol. (2011) 22: 2675-2686.
28. Hamkar R and Mokhtari Azad T. Prevalence of variouse types of HPV among cervical cancer and normal biopsy in north of Iran. Iran. J. Infec. Dis. Tropical Medicine. (2004) 8: 22-29.
29. Elbasha EH, Dasbach EJ and Insinga RP. Model for assessing human papillomavirus vaccination strategies Emerg. Infect. Dis. (2007) 13: 28-41.
30. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF and Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine (2011) 29: 8443-8450.
31. Gold MR, Siegel JE, Russell LB and Weinstein MC. (eds.) Cost-effectiveness in health and medicine. Oxford University Press, New York (1996).
32. Haddix AC, Teutsch SM and CorsoPS. (eds.) Prevention effectiveness: a guide to decision analysis and economic evaluation, 2nd ed. Oxford University Press, New York (2003).
33. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B and Roteli-Martins CM. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. (2006) 367: 1247-1255.
34. US Cancer Statistics Working Group. United States cancer statistics: 2003 incidence and mortality. Atlanta: Centers for Disease Control and Prevention and National Cancer Institute. (2006).
35. Hankey BF, Ries LA and Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol. Biomarkers Prev. (1999) 8: 1117-1121.
36. Watson M, Saraiya M, Weir H and Ahmed F. Leading partnerships to assess the burden of HPV-related cancers. 2007 CDC Cancer. Atlanta: Centers for Disease Control and Prevention (2007) 2: 1-5.
37. Insinga RP, Glass AG and Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am. J. Obstet. Gynecol. (2004) 191: 105-113.
38. Iran ministry of health and medical education: Tariff of healthcare services in public and private sectors in Iran (2012). Iran ministry of health and medical education press, Tehran (2012).
39. Gold MR, Franks P, McCoy KI and Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med. Care. (1998) 36: 778-792.
40. Kulasingam SL and Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. (2003) 290: 781-789.
41. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC and Bosch FX. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. (2004) 96: 604-615.
42. Institute of Medicine. Vaccines for the 21st century: A tool for decision making. Washington, DC: National Academy of Sciences. (2000).
43. Kim JJ, Wright TC and Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. (2002) 287: 2382-2390.
44. Drummond MF and Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. British Med. J. (1996) 313: 275-283.
45. Eichler HG, Kong SX, Gerth WC, Mavros P and Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How is cost-effectiveness thresholds expected to emerge? Value in Health (2004) 7: 518-528.
46. Grosse SD. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Rev. Pharmacoeconomics Res. (2008) 8: 165-178.
47. NICE. NHS. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (accessed July 23, 2008) URL is availablefrom:URL: http://www.nice.org.uk/media/B52/A7/
48. Devlin N and Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. (2004) 13: 437-452.
49. WHO. World Health Organization. Choosing Interventions that are Cost Effective (WHOCHOICE) Tables of costs and prices used in WHO-CHOICE analysis.(accessed July 28, 2008). URL is available from: URL: http://www.who.int/choice/costs/CER_levels/en/index.html.
50. Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K and Meinikow J. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet. Gynecol. (2006) 107: 321-328.
51. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer (2007) 111: 145-153.
52. Haupt RM. GARDASIL update. CDC Cancer Conference Program of Events; Atlanta. Centers for Disease Control and Prevention (2007).